Program
penpulimab
Also written as “AK105”, “Penpulimab” and “Penpulimab injection”.
Its studies are mostly in Carcinoma, Hepatocellular · Nasopharyngeal Carcinoma · Carcinoma, Non-Small-Cell Lung · Hodgkin Disease · Esophageal Squamous Cell Carcinoma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 187 open or running | phase 3since Apr 10, 2020 | Dec 17, 2019 | Dec 2026phase 3 · NCT04344158 |
| Akeso | 92 open or running | phase 3since Mar 6, 2019 | Nov 21, 2017 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 12 studies since Nov 21, 2017.
- Jul 13, 2021Phase 3 study in Nasopharyngeal CarcinomaAkeso · NCT04974398 · 296 enrolled · United States, Australia, Brazil and more
- Sep 24, 2021Phase 2 study in Unresectable Metastatic Colorectal CancerSino Biopharmaceutical · NCT05068206 · 120 enrolled · China
- Jan 25, 2022Phase 3 study in Hodgkin Disease LymphomaAkeso · NCT05244642 · 60 planned · China
- Apr 12, 2022Phase 1 study in Advanced CancersSino Biopharmaceutical · NCT05333276 · 7 enrolled · China
- May 16, 2022Phase 2 study in LymphomaSino Biopharmaceutical · NCT05400876 · 92 enrolled · China
- Sep 27, 2022Phase 2 study in Nasopharyngeal CarcinomaSino Biopharmaceutical · NCT05563480 · 47 enrolled · China
- Apr 18, 2023Phase 2 study in Advanced Esophageal Squamous Cell CarcinomaSino Biopharmaceutical · NCT05834543 · 34 enrolled · China
- May 15, 2023Phase 3 study in Carcinoma, HepatocellularSino Biopharmaceutical · NCT05862337 · 480 planned · China
- May 31, 2023Phase 1 study in Advanced CancerSino Biopharmaceutical · NCT05894421 · 92 planned · China
- Jul 27, 2023Phase 1 study in Advanced Hepatocellular CarcinomaSino Biopharmaceutical · NCT05975645 · 29 enrolled · China
- Mar 1, 20242 phase 1 studiesSino Biopharmaceutical · NCT06297642, NCT06320080
- Jul 8, 2024Phase 2 study in SarcomaSino Biopharmaceutical · NCT06500091 · 54 planned · China
- Jan 6, 2025Phase 2 study in Gastroesophageal AdenocarcinomaSino Biopharmaceutical · NCT06767800 · 204 planned · China
- Feb 9, 2025Phase 2 study in Advanced Solid TumorSino Biopharmaceutical · NCT06825494 · 194 planned · China
Ahead
- Dec 2026Primary completion: phase 3 study in Advanced Hepatocellular Carcinoma (HCC)Sino Biopharmaceutical · NCT04344158
TargetBeta
“A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06825494Advanced Solid Tumor · China | 2 | Recruiting | Sino Biopharmaceutical | Mar 2026 | 194 |
| NCT06767800Gastroesophageal Adenocarcinoma · China | 2 | Recruiting | Sino Biopharmaceutical | Sep 2026 | 204 |
| NCT06500091Sarcoma · China | 2 | Not yet recruiting | Sino Biopharmaceutical | Jun 2026 | 54 |
| NCT06320080Advanced Hepatocellular Carcinoma · China | 1 | Terminated | Sino Biopharmaceutical | Nov 3, 2025 | 22 |
| NCT06297642Advanced Malignant Neoplasm · China | 1 | Terminated | Sino Biopharmaceutical | Jul 31, 2024 | 3 |
| NCT05975645Advanced Hepatocellular Carcinoma · China | 1 | Terminated | Sino Biopharmaceutical | Jun 4, 2025 | 29 |
| NCT05894421Advanced Cancer · China | 1 | Recruiting | Sino Biopharmaceutical | Jan 2025 | 92 |
| NCT05862337Carcinoma, Hepatocellular · China | 3 | Recruiting | Sino Biopharmaceutical | Aug 2024 | 480 |
| NCT05834543Advanced Esophageal Squamous Cell Carcinoma · China | 2 | Terminated | Sino Biopharmaceutical | Oct 23, 2024 | 34 |
| NCT05563480Nasopharyngeal Carcinoma · China | 2 | Completed | Sino Biopharmaceutical | May 28, 2025 | 47 |
| NCT05400876Lymphoma · China | 2 | UNKNOWN | Sino Biopharmaceutical | May 2023 | 92 |
| NCT05333276Advanced Cancers · China | 1 | Active, not recruiting | Sino Biopharmaceutical | Dec 2023 | 7 |
| NCT05244642Hodgkin Disease Lymphoma · China | 3 | Recruiting | Akeso | Dec 30, 2025 | 60 |
| NCT05068206Unresectable Metastatic Colorectal Cancer · China | 2 | UNKNOWN | Sino Biopharmaceutical | Dec 2023 | 120 |
| NCT04974398Nasopharyngeal Carcinoma · United States, Australia, Brazil and more | 3 | Active, not recruiting | Akeso | Feb 23, 2026 | 296 |
| NCT04385550Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma · China | 3 | UNKNOWN | Sino Biopharmaceutical | Oct 31, 2023 | 528 |
| NCT04344158Advanced Hepatocellular Carcinoma (HCC) · China | 3 | Active, not recruiting | Sino Biopharmaceutical | Dec 2026 | 648 |
| NCT04291248MSI-H or dMMR Advanced Solid Tumors · China | 2 | UNKNOWN | Sino Biopharmaceutical | Dec 2022 | 138 |
| NCT04207463Digestive System Neoplasms · China | 2 | UNKNOWN | Sino Biopharmaceutical | Dec 31, 2020 | 150 |
| NCT04203719Advanced Head, Neck and Chest Cancer · China | 2 | UNKNOWN | Sino Biopharmaceutical | Dec 31, 2020 | 140 |
| NCT04172571Carcinoma, Hepatocellular · China | 2 | Completed | Akeso | Jun 1, 2022 | 31 |
| NCT04172506Lung Neoplasms · China | 2 | Completed | Akeso | Dec 1, 2021 | 65 |
| NCT03866993Carcinoma, Non-Small-Cell Lung · China | 3 | Completed | Akeso | Oct 8, 2020 | 350 |
| NCT03866980Carcinoma, Non-Small-Cell Lung · China | 3 | Terminated | Akeso | Jun 30, 2023 | 164 |
| NCT03866967Nasopharyngeal Carcinoma · China | 2 | Completed | Akeso | Mar 13, 2021 | 130 |
| NCT03722147Hodgkin Disease · China | 2 | Completed | Akeso | Jan 10, 2020 | 94 |
| NCT03352531Advanced Cancer · Australia | 1 | Completed | Akeso | Nov 30, 2020 | 99 |
How it is read
Names in the registry
- “AK105”, 9 entries
- “Penpulimab”, 3 entries
- “Penpulimab injection”, 2 entries
- “AK105 injection”, 2 entries
- “TQB2618 injection; Penpulimab injection”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 5 studies
- Nasopharyngeal Carcinoma, 3 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Hodgkin Disease, 2 studies
- Esophageal Squamous Cell Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.